ASTRAZENECA PHARMA INDIA LIMITED

AstraZeneca Pharma India Limited is primarily a pharmaceutical manufacturer.

AstraZeneca Pharma India Limited (AZPIL) is the Indian subsidiary of AstraZeneca PLC, a leading global biopharmaceutical company headquartered in the United Kingdom. AZPIL is engaged in the research, development, manufacturing, and commercialization of prescription medicines in India. The company focuses on a range of therapeutic areas, including Oncology, Cardiovascular, Renal and Metabolism (CVRM), and Respiratory & Immunology. Its mission is to deliver innovative and life-changing medicines to patients in India, addressing unmet medical needs and improving health outcomes. AZPIL operates with a strong commitment to local manufacturing and distribution capabilities to serve the Indian market effectively. The company is publicly listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) in India.

Products manufactured or marketed by ASTRAZENECA PHARMA INDIA LIMITED in India:

* Brilinta (Ticagrelor)

* Forxiga (Dapagliflozin)

* Xigduo XR (Dapagliflozin and Metformin Hydrochloride)

* Qtern (Dapagliflozin and Saxagliptin)

* Onglyza (Saxagliptin)

* Kombiglyze XR (Saxagliptin and Metformin Hydrochloride)

* Bydureon (Exenatide extended-release)

* Byetta (Exenatide)

* Farxiga (Dapagliflozin)

* Symbicort (Budesonide and Formoterol Fumarate Dihydrate)

* Pulmicort (Budesonide)

* Roxadustat (Evrenzo)

* Calquence (Acalabrutinib)

* Tagrisso (Osimertinib)